Physicians

Rulers made of a thin, and wipeable PVC material for measuring skin test reactions from the Mantoux tuberculin skin test. The rulers are available for order in quantities of 25 or 100.

The resource was designed to help healthcare providers:
1. Quickly identify and answer key questions when considering whether to start a patient on the isoniazid-rifapentine (3HP) regimen
2. Assess the appropriateness of self-administered therapy of 3HP for each individual patient
3. Ensure that the correct drugs for the 3HP regimen are prescribed and provided to the patient
4. Handle questions on side effects and adverse reactions for a patient currently on the 3HP regimen

The operational handbook provides information on how to implement the WHO recommendations, tools, job-aids, and monitoring and evaluation indicators for the programmatic management of tuberculosis preventive treatment. The Module 1 handbook complements Module 1 of the WHO consolidated guidelines on tuberculosis.

The resource provides recommendations for the programmatic management of tuberculosis preventive treatment. Modules of the WHO consolidated guidelines on tuberculosis are complemented by matching modules of the WHO operational handbook on tuberculosis.

In this webinar, participants hear from public health professionals about the impact of COVID-19 on TB program services. Topics addressed include programmatic adjustments during COVID-19, changes in clinical care and community work, and TB control activities during COVID-19.  The webinar also provides information on various TB and COVID-19 resources.

By the end of this webinar, participants will be able to: explain the impact that population mobility bears on public health within the context of globalization, outline strategies and approaches for addressing challenges of TB management and care among migrants,  and develop strategies and best practices to address medical and community management of migrant population.

This material aims to inform national TB Programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.

The resource is intended for primary care providers who care for individuals and populations who may be at risk for infection with M. tuberculosis. The guide includes latent TB infection diagnosis and treatment information, sample documentation forms, and additional resources.

This material summarizes the U.S. recommendations for latent TB infection testing and treatment. The document includes information on who should be tested for TB infection, recommended treatment regimens for latent TB infection, and more.

This document informs national TB programs and stakeholders about the key implications for the treatment of drug-resistant tuberculosis. This resource is available before the release of the updated guidelines in order for planning at the country level. The guidelines are expected to be released in 2020.